Recent ATAI News
- AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs • GlobeNewswire Inc. • 04/08/2026 10:00:00 AM
- AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst • GlobeNewswire Inc. • 03/24/2026 10:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/20/2026 08:41:49 PM
- BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation • GlobeNewswire Inc. • 03/17/2026 10:00:00 AM
- BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day • GlobeNewswire Inc. • 03/10/2026 10:00:00 AM
- CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions • PR Newswire (US) • 03/09/2026 02:50:00 PM
- CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions • PR Newswire (Canada) • 03/09/2026 02:50:00 PM
- AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update • GlobeNewswire Inc. • 03/06/2026 12:00:00 PM
- AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression • GlobeNewswire Inc. • 03/03/2026 12:00:00 PM
- Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments • PR Newswire (US) • 02/27/2026 04:44:00 PM
- Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments • PR Newswire (Canada) • 02/27/2026 04:44:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2026 09:11:03 PM
- AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder • GlobeNewswire Inc. • 02/26/2026 12:00:00 PM
- AtaiBeckley To Host Virtual Investor Day on March 6, 2026 • GlobeNewswire Inc. • 02/20/2026 12:00:00 PM
- AtaiBeckley Appoints Michael Faerm as Chief Financial Officer • GlobeNewswire Inc. • 02/19/2026 12:00:00 PM
- AtaiBeckley To Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 02/17/2026 12:00:00 PM
- AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation • GlobeNewswire Inc. • 01/16/2026 12:00:00 PM
- AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 12/31/2025 02:01:02 AM
- Form POSASR - Post-effective Amendment to an automatic shelf registration statement • Edgar (US Regulatory) • 12/31/2025 01:49:58 AM
- AtaiBeckley Completes Redomiciliation to the United States • GlobeNewswire Inc. • 12/31/2025 12:13:02 AM
- AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI) • GlobeNewswire Inc. • 12/23/2025 12:00:00 PM
- AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio • GlobeNewswire Inc. • 12/11/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2025 09:56:59 PM
- Form 424B7 - Prospectus [Rule 424(b)(7)] • Edgar (US Regulatory) • 12/05/2025 09:43:42 PM
